标题:The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era
作者:Zheng Y.; Sun Y.; Yang H.; Liu J.; Xing L.; Sun Y.
作者机构:[Zheng, Y] Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong First Medical University, No. 10 更多
通讯作者:Sun, Y(13370582181@163.com)
通讯作者地址:[Sun, Y] Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong First Medical University, Departme 更多
来源:European Journal of Health Economics
出版年:2020
卷:21
期:8
页码:1223-1233
DOI:10.1007/s10198-020-01223-7
关键词:Income disparities; Metastatic clear cell renal cell carcinoma; Survival gaps; Targeted therapy era
摘要:Purpose: The influence of socioeconomic status on metastatic clear cell renal cell carcinoma (RCC) in the target therapy era is still unknown. This study aimed to assess the role of income disparities on prognosis of mRCC in the targeted therapy era. Patients and methods: Data of patients with mRCC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Median household income (MHI) was used to represent patients’ socioeconomic status, and its role on overall survival (OS) and cancer-specific survival (CSS) was evaluated. Results: A total of 3791 patients with clear cell mRCC diagnosed between 2010 and 2015 were enrolled in cohort one. There was an obvious imbalance of race and insurance status in patients with difference MHI. Compared with patients in the poorest quartile 1 (Q1), those in the wealthiest Q4 had a 4-month prolonged OS (P < 0.01) and a 5-month prolonged CSS (P < 0.01), and those in Q3 and Q4 had significantly lower death risk. High income decreased cumulative cancer-specific mortality rates, and potentially favored survival in most subgroups. 6619 patients diagnosed between 2004 and 2015 were included in cohort two. We found that only those with Q4 income achieved a prolonged survival with statistical significance by comparing between patients diagnosed in 2004–2009 and 2010–2015. Conclusion: In the targeted therapy era, there were survival gaps of mRCC between patients with low- and high-income. Measures should be taken to develop a comprehensive and financially sustainable plan of cancer treatment for greater equity. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
收录类别:SCOPUS
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088789641&doi=10.1007%2fs10198-020-01223-7&partnerID=40&md5=62dc56555a335246871e800623acace3
TOP